Skip to main content
Top
Published in: Current Atherosclerosis Reports 9/2013

01-09-2013 | Nutrition (BV Howard, Section Editor)

Recent Economic Evaluations of Interventions to Prevent Cardiovascular Disease by Reducing Sodium Intake

Authors: Guijing Wang, Barbara A. Bowman

Published in: Current Atherosclerosis Reports | Issue 9/2013

Login to get access

Abstract

Excess intake of sodium, a common problem worldwide, is associated with hypertension and cardiovascular disease (CVD), and hypertension is a major risk factor for CVD. Population-wide efforts to reduce sodium intake have been identified as a promising strategy for preventing hypertension and CVD, and such initiatives are currently recommended by a variety of scientific and public health organizations. By reviewing the literature published from January 2011 to March 2013, we summarized recent economic analyses of interventions to reduce sodium intake. The evidence, derived from estimates of resultant blood pressure decreases and thus decreases in the incidence of CVD events, supports population-wide interventions for reducing sodium intake. Both lowering the salt content in manufactured foods and conducting mass media campaigns at the national level are estimated to be cost-effective in preventing CVD. Although better data on the cost of interventions are needed for rigorous economic evaluations, population-wide sodium intake reduction can be a promising approach for containing the growing health and economic burden associated with hypertension and its sequelae.
Literature
1.
go back to reference World Health Organization. Global status report on noncommunicable diseases 2010. Geneva: WHO; 2011. World Health Organization. Global status report on noncommunicable diseases 2010. Geneva: WHO; 2011.
2.
go back to reference Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.PubMedCrossRef Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.PubMedCrossRef
3.
go back to reference Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics─2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-245. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics─2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-245.
4.
go back to reference Leal J, Luengo-Fernández R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J. 2006;27:1610–9.PubMedCrossRef Leal J, Luengo-Fernández R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J. 2006;27:1610–9.PubMedCrossRef
5.
go back to reference Luengo-Fernández R, Leal J, Gray A, Petersen S, Rayner M. Cost of cardiovascular diseases in the United Kingdom. Heart. 2006;92:1384–9.PubMedCrossRef Luengo-Fernández R, Leal J, Gray A, Petersen S, Rayner M. Cost of cardiovascular diseases in the United Kingdom. Heart. 2006;92:1384–9.PubMedCrossRef
9.
go back to reference Morrison AC, Ness RB. Sodium intake and cardiovascular disease. Annu Rev Public Health. 2011;32:71–90.PubMedCrossRef Morrison AC, Ness RB. Sodium intake and cardiovascular disease. Annu Rev Public Health. 2011;32:71–90.PubMedCrossRef
10.
go back to reference He FJ, MacGregor GA. Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials. Lancet. 2011;378:380–2.PubMedCrossRef He FJ, MacGregor GA. Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials. Lancet. 2011;378:380–2.PubMedCrossRef
11.
go back to reference Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007;334:885–8.PubMedCrossRef Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007;334:885–8.PubMedCrossRef
12.
go back to reference Graudal NA, Hubeck-Graudal T, Jürgens G. Effects of low-sodium diet vs. high-sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review). Am J Hypertens. 2012;25:1–15.PubMedCrossRef Graudal NA, Hubeck-Graudal T, Jürgens G. Effects of low-sodium diet vs. high-sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review). Am J Hypertens. 2012;25:1–15.PubMedCrossRef
13.
go back to reference O’Donnell MJ, Yusuf S, Mente A, et al. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA. 2011;306:2229–38.PubMedCrossRef O’Donnell MJ, Yusuf S, Mente A, et al. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA. 2011;306:2229–38.PubMedCrossRef
14.
go back to reference He FJ, Campbell NR, MacGregor GA. Reducing salt intake to prevent hypertension and cardiovascular disease. Rev Panam Salud Publica. 2012;32:293–300.PubMedCrossRef He FJ, Campbell NR, MacGregor GA. Reducing salt intake to prevent hypertension and cardiovascular disease. Rev Panam Salud Publica. 2012;32:293–300.PubMedCrossRef
15.
go back to reference Strazzullo P, D’Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. BMJ. 2009;339:b4567.PubMedCrossRef Strazzullo P, D’Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. BMJ. 2009;339:b4567.PubMedCrossRef
16.
go back to reference Coxson PG, Cook NR, Joffres M, et al. Mortality benefits from US population-wide reduction in sodium consumption: projections from 3 modeling approaches. Hypertension. 2013;61:564–70.PubMedCrossRef Coxson PG, Cook NR, Joffres M, et al. Mortality benefits from US population-wide reduction in sodium consumption: projections from 3 modeling approaches. Hypertension. 2013;61:564–70.PubMedCrossRef
17.
go back to reference D’Elia L, Barba G, Cappuccio FP, Strazzullo P. Potassium intake, stroke, and cardiovascular disease: a meta-analysis of prospective studies. J Am Coll Cardiol. 2011;57:1210–9.PubMedCrossRef D’Elia L, Barba G, Cappuccio FP, Strazzullo P. Potassium intake, stroke, and cardiovascular disease: a meta-analysis of prospective studies. J Am Coll Cardiol. 2011;57:1210–9.PubMedCrossRef
18.
go back to reference Appel LJ, Frohlich ED, Hall JE, et al. The importance of population-wide sodium reduction as a means to prevent cardiovascular disease and stroke: a call to action from the American Heart Association. Circulation. 2011;123:1138–43.PubMedCrossRef Appel LJ, Frohlich ED, Hall JE, et al. The importance of population-wide sodium reduction as a means to prevent cardiovascular disease and stroke: a call to action from the American Heart Association. Circulation. 2011;123:1138–43.PubMedCrossRef
19.
go back to reference Stolarz-Skrzypek K, Kuznetsova T, Thijs L, et al. Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. JAMA. 2011;305:1777–85.PubMedCrossRef Stolarz-Skrzypek K, Kuznetsova T, Thijs L, et al. Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. JAMA. 2011;305:1777–85.PubMedCrossRef
20.
go back to reference Whelton PK, Appel LJ, Sacco RL, et al. Sodium, blood pressure, and cardiovascular disease: further evidence supporting the American Heart Association sodium reduction recommendations. Circulation. 2012;126:2880–9.PubMedCrossRef Whelton PK, Appel LJ, Sacco RL, et al. Sodium, blood pressure, and cardiovascular disease: further evidence supporting the American Heart Association sodium reduction recommendations. Circulation. 2012;126:2880–9.PubMedCrossRef
21.
go back to reference Tomonari T, Fukuda M, Miura T, et al. Is salt intake an independent risk factor of stroke mortality? Demographic analysis by regions in Japan. J Am Soc Hypertens. 2011;5:456–62.PubMedCrossRef Tomonari T, Fukuda M, Miura T, et al. Is salt intake an independent risk factor of stroke mortality? Demographic analysis by regions in Japan. J Am Soc Hypertens. 2011;5:456–62.PubMedCrossRef
22.
go back to reference Gardener H, Rundek T, Wright CB, Elkind MS, Sacco RL. Dietary sodium and risk of stroke in the Northern Manhattan study. Stroke. 2012;43:1200–5.PubMedCrossRef Gardener H, Rundek T, Wright CB, Elkind MS, Sacco RL. Dietary sodium and risk of stroke in the Northern Manhattan study. Stroke. 2012;43:1200–5.PubMedCrossRef
23.
go back to reference • Alderman MH, Cohen HW. Dietary sodium intake and cardiovascular mortality controversy resolved? AJH. 2012. doi:10.1038/ajh.2012.52. Although population-wide efforts to reduce sodium intake are promising for preventing hypertension and CVD, this study warned that robust evidence does not support universal reduction of sodium intake. For individuals whose diet falls outside the “safe” range of sodium intake, there is no evidence that reducing sodium intake will lead to better health outcomes.. • Alderman MH, Cohen HW. Dietary sodium intake and cardiovascular mortality controversy resolved? AJH. 2012. doi:10.​1038/​ajh.​2012.​52. Although population-wide efforts to reduce sodium intake are promising for preventing hypertension and CVD, this study warned that robust evidence does not support universal reduction of sodium intake. For individuals whose diet falls outside the “safe” range of sodium intake, there is no evidence that reducing sodium intake will lead to better health outcomes..
25.
26.
go back to reference World Health Organization. Reducing salt intake in populations: report of a WHO forum and technical meeting. Geneva: WHO; 2007. World Health Organization. Reducing salt intake in populations: report of a WHO forum and technical meeting. Geneva: WHO; 2007.
30.
go back to reference Dalziel K, Segal L, Mortimer D. Review of Australia health economic evaluation─245 interventions: what can we say about cost-effectiveness? Cost Eff Resour Alloc. 2008;6:9.PubMedCrossRef Dalziel K, Segal L, Mortimer D. Review of Australia health economic evaluation─245 interventions: what can we say about cost-effectiveness? Cost Eff Resour Alloc. 2008;6:9.PubMedCrossRef
31.
go back to reference Schwappach DLB, Boluarte TA, Suhrcke M. The economics of primary prevention of cardiovascular disease─a systematic review of economic evaluations. Cost Eff Resour Alloc. 2007;5:5.PubMedCrossRef Schwappach DLB, Boluarte TA, Suhrcke M. The economics of primary prevention of cardiovascular disease─a systematic review of economic evaluations. Cost Eff Resour Alloc. 2007;5:5.PubMedCrossRef
32.
go back to reference Rubinstein A, Garcia Marti S, Souto A, Ferrante D, Augustovski F. Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina. Cost Eff Resour Alloc. 2009;7:10.PubMedCrossRef Rubinstein A, Garcia Marti S, Souto A, Ferrante D, Augustovski F. Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina. Cost Eff Resour Alloc. 2009;7:10.PubMedCrossRef
34.
go back to reference Kind P, Lafata JE, Matuszewski K, Raisch D. The use of QALYs in clinical and patient decision-making: issues and prospects. Value Health. 2009;12 Suppl 1:S27–30.PubMedCrossRef Kind P, Lafata JE, Matuszewski K, Raisch D. The use of QALYs in clinical and patient decision-making: issues and prospects. Value Health. 2009;12 Suppl 1:S27–30.PubMedCrossRef
36.
go back to reference •• Gase LN, Kuo T, Dunet D, Schmidt SM, Simon PA, Fielding JE. Estimating the potential health impact and costs of implementing a local policy for food procurement to reduce the consumption of sodium in the county of Los Angeles. Am J Public Health. 2011;101:1501–7. Although this study only focused on a local policy at a county level, the approaches in estimating the health impact as well as the costs of implementation can be applied to other settings. It provided an empirical framework of policy evaluation by estimating both the health impact and the cost of implementation. This is a good step toward developing practical intervention programs..PubMedCrossRef •• Gase LN, Kuo T, Dunet D, Schmidt SM, Simon PA, Fielding JE. Estimating the potential health impact and costs of implementing a local policy for food procurement to reduce the consumption of sodium in the county of Los Angeles. Am J Public Health. 2011;101:1501–7. Although this study only focused on a local policy at a county level, the approaches in estimating the health impact as well as the costs of implementation can be applied to other settings. It provided an empirical framework of policy evaluation by estimating both the health impact and the cost of implementation. This is a good step toward developing practical intervention programs..PubMedCrossRef
37.
go back to reference Barton P, Andronis L, Briggs A, McPherson K, Capewell S. Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study. BMJ. 2011;28:343. d4044. Barton P, Andronis L, Briggs A, McPherson K, Capewell S. Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study. BMJ. 2011;28:343. d4044.
38.
go back to reference Martikainen JA, Soini EJ, Laaksonen DE, Niskanen L. Health economic consequences of reducing salt intake and replacing saturated fat with polyunsaturated fat in the adult Finnish population: estimates based on the FINRISK and FINDIET studies. Eur J Clin Nutr. 2011;65:1148–55.PubMedCrossRef Martikainen JA, Soini EJ, Laaksonen DE, Niskanen L. Health economic consequences of reducing salt intake and replacing saturated fat with polyunsaturated fat in the adult Finnish population: estimates based on the FINRISK and FINDIET studies. Eur J Clin Nutr. 2011;65:1148–55.PubMedCrossRef
39.
go back to reference Ha DA, Chisholm D. Cost-effectiveness analysis of interventions to prevent cardiovascular disease in Vietnam. Health Policy Plan. 2011;26:210–22.PubMedCrossRef Ha DA, Chisholm D. Cost-effectiveness analysis of interventions to prevent cardiovascular disease in Vietnam. Health Policy Plan. 2011;26:210–22.PubMedCrossRef
40.
go back to reference •• Cobiac LJ, Magnus A, Lim S, Barendregt JJ, Carter R, Vos T. Which interventions offer best value for money in primary prevention of cardiovascular disease? PLoS One. 2012;7:e41842. This study evaluated various interventions including lifestyle, pharmaceutical, and population-wide interventions over the lifetime of Australian adults in one complex model. The authors proved that the Australian government must enforce moderate salt limits in some processed foods for large and immediate improvement in the health of the population..PubMedCrossRef •• Cobiac LJ, Magnus A, Lim S, Barendregt JJ, Carter R, Vos T. Which interventions offer best value for money in primary prevention of cardiovascular disease? PLoS One. 2012;7:e41842. This study evaluated various interventions including lifestyle, pharmaceutical, and population-wide interventions over the lifetime of Australian adults in one complex model. The authors proved that the Australian government must enforce moderate salt limits in some processed foods for large and immediate improvement in the health of the population..PubMedCrossRef
41.
go back to reference Ferrante D, Konfino J, Mejía R, et al. The cost-utility ratio of reducing salt intake and its impact on the incidence of cardiovascular disease in Argentina [in Spanish]. Rev Panam Salud Publica. 2012;32:274–80.PubMedCrossRef Ferrante D, Konfino J, Mejía R, et al. The cost-utility ratio of reducing salt intake and its impact on the incidence of cardiovascular disease in Argentina [in Spanish]. Rev Panam Salud Publica. 2012;32:274–80.PubMedCrossRef
42.
go back to reference Wang G, Labarthe D. The cost-effectiveness of interventions designed to reduce sodium intake. J Hypertens. 2011;29:1693–9.PubMedCrossRef Wang G, Labarthe D. The cost-effectiveness of interventions designed to reduce sodium intake. J Hypertens. 2011;29:1693–9.PubMedCrossRef
43.
go back to reference Heidenreich PA, Trogdon JG, Khavjou OA. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933–44.PubMedCrossRef Heidenreich PA, Trogdon JG, Khavjou OA. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933–44.PubMedCrossRef
44.
go back to reference • Appel LJ, Angel SY, Cobb LK, et al. Population-wide sodium reduction: the bumpy road from evidence to policy. Ann Epidemiol. 2012;22:417–25. This study emphasized that cost-effectiveness modeling clearly has a valuable role in policy-making. The results of the economic evaluation can be used to prioritize public health interventions such as population-wide salt intake reduction. Furthermore, the authors offered a number of lessons learned in translating epidemiologic and other scientific findings into policy..PubMedCrossRef • Appel LJ, Angel SY, Cobb LK, et al. Population-wide sodium reduction: the bumpy road from evidence to policy. Ann Epidemiol. 2012;22:417–25. This study emphasized that cost-effectiveness modeling clearly has a valuable role in policy-making. The results of the economic evaluation can be used to prioritize public health interventions such as population-wide salt intake reduction. Furthermore, the authors offered a number of lessons learned in translating epidemiologic and other scientific findings into policy..PubMedCrossRef
45.
46.
go back to reference Smith-Spangler CM, Juusola JL, Enns EA, Owens DK, Garber AM. Population strategies to decrease sodium intake and the burden of cardiovascular disease: a cost-effectiveness analysis. Ann Intern Med. 2010;152:481–7.PubMedCrossRef Smith-Spangler CM, Juusola JL, Enns EA, Owens DK, Garber AM. Population strategies to decrease sodium intake and the burden of cardiovascular disease: a cost-effectiveness analysis. Ann Intern Med. 2010;152:481–7.PubMedCrossRef
47.
go back to reference Bibbins-Domingo K, Chertow GM, Coxson PG, et al. Projected effect of dietary salt reduction on future cardiovascular disease. N Engl J Med. 2012;362:590–9.CrossRef Bibbins-Domingo K, Chertow GM, Coxson PG, et al. Projected effect of dietary salt reduction on future cardiovascular disease. N Engl J Med. 2012;362:590–9.CrossRef
48.
go back to reference Palar K, Sturm R. Potential societal savings from reduced sodium consumption in the U.S. adult population. Am J Health Promot. 2009;24:49–57.PubMedCrossRef Palar K, Sturm R. Potential societal savings from reduced sodium consumption in the U.S. adult population. Am J Health Promot. 2009;24:49–57.PubMedCrossRef
49.
go back to reference Dall TM, Fulgoni 3rd VL, Zhang Y, et al. Potential health benefits and medical cost savings from calorie, sodium, and saturated fat reductiuons in the American diet. Am J Health Promot. 2009;23:412–22.PubMedCrossRef Dall TM, Fulgoni 3rd VL, Zhang Y, et al. Potential health benefits and medical cost savings from calorie, sodium, and saturated fat reductiuons in the American diet. Am J Health Promot. 2009;23:412–22.PubMedCrossRef
50.
go back to reference Dall TM, Fulgoni 3rd VL, Zhang Y, et al. Predicted national productivity implications of calorie and sodium reductions in the American diet. Am J Health Promot. 2009;23:423–30.PubMedCrossRef Dall TM, Fulgoni 3rd VL, Zhang Y, et al. Predicted national productivity implications of calorie and sodium reductions in the American diet. Am J Health Promot. 2009;23:423–30.PubMedCrossRef
51.
go back to reference Asaria P, Chisholm D, Mathers C, et al. Chronic disease prevention: health benefits and financial costs of strategies to reduce salt intake and control tobacco use. Lancet. 2007;370:2044–53.PubMedCrossRef Asaria P, Chisholm D, Mathers C, et al. Chronic disease prevention: health benefits and financial costs of strategies to reduce salt intake and control tobacco use. Lancet. 2007;370:2044–53.PubMedCrossRef
52.
go back to reference Murray CJ, Lauer JA, Hutubessy RC, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet. 2003;361:717–25.PubMedCrossRef Murray CJ, Lauer JA, Hutubessy RC, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet. 2003;361:717–25.PubMedCrossRef
Metadata
Title
Recent Economic Evaluations of Interventions to Prevent Cardiovascular Disease by Reducing Sodium Intake
Authors
Guijing Wang
Barbara A. Bowman
Publication date
01-09-2013
Publisher
Springer US
Published in
Current Atherosclerosis Reports / Issue 9/2013
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-013-0349-1

Other articles of this Issue 9/2013

Current Atherosclerosis Reports 9/2013 Go to the issue

Cardiovascular Disease and Stroke (D Leifer and JE Safdieh, Section Editors)

Review of Stroke Center Effectiveness and Other Get with the Guidelines Data

Clinical Trials and Their Interpretations (J Plutzky, Section Editor)

Atherosclerosis and Transit of HDL Through the Lymphatic Vasculature

Clinical Trials and Their Interpretations (J Plutzky, Section Editor)

Hypoglycemia as a Driver of Cardiovascular Risk in Diabetes

Clinical Trials and Their Interpretations (J Plutzky, Section Editor)

Nuclear Reprogramming and Its Role in Vascular Smooth Muscle Cells

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.